154 related articles for article (PubMed ID: 35790259)
21. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Taguchi S; Kawai T; Buti S; Bersanelli M; Uemura Y; Kishitani K; Miyakawa J; Sugimoto K; Nakamura Y; Niimi F; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Kanazawa K; Sugihara Y; Tokunaga M; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
Immunotherapy; 2023 Aug; 15(11):827-837. PubMed ID: 37191002
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study.
Taguchi S; Kawai T; Nakagawa T; Nakamura Y; Kamei J; Obinata D; Yamaguchi K; Kaneko T; Kakutani S; Tokunaga M; Uemura Y; Sato Y; Fujimura T; Fukuhara H; Enomoto Y; Nishimatsu H; Takahashi S; Kume H
Sci Rep; 2021 Aug; 11(1):15623. PubMed ID: 34341416
[TBL] [Abstract][Full Text] [Related]
24. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
25. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
26. Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.
Alnajar H; Ravichandran H; Figueiredo Rendeiro A; Ohara K; Al Zoughbi W; Manohar J; Greco N; Sigouros M; Fox J; Muth E; Angiuoli S; Faltas B; Shusterman M; Sternberg CN; Elemento O; Mosquera JM
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483877
[TBL] [Abstract][Full Text] [Related]
27. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
Fukushima H; Kijima T; Fukuda S; Moriyama S; Uehara S; Yasuda Y; Tanaka H; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Matsubara N; Numao N; Sakai Y; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Med; 2020 Nov; 9(22):8355-8363. PubMed ID: 32886446
[TBL] [Abstract][Full Text] [Related]
28. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2021 Dec; 39(12):834.e21-834.e28. PubMed ID: 34284929
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
31. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
[TBL] [Abstract][Full Text] [Related]
32. Update of systemic immunotherapy for advanced urothelial carcinoma.
Gartrell BA; He T; Sharma J; Sonpavde G
Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
[TBL] [Abstract][Full Text] [Related]
33. Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder.
Kim HS; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
Sci Rep; 2015 May; 5():9626. PubMed ID: 25959144
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
[TBL] [Abstract][Full Text] [Related]
35. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
Yasuoka S; Yuasa T; Nishimura N; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Jul; 39(7):3887-3892. PubMed ID: 31262917
[TBL] [Abstract][Full Text] [Related]
36. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2022 Jan; 27(1):59-71. PubMed ID: 34757531
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Tomisaki I; Harada M; Sakano S; Terado M; Hamasuna R; Harada S; Matsumoto H; Akasaka S; Nagata Y; Minato A; Harada KI; Fujimoto N
Int J Urol; 2023 Sep; 30(9):738-745. PubMed ID: 36693764
[TBL] [Abstract][Full Text] [Related]
39. Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients.
Inoue S; Sassa N; Kato T; Yamauchi Y; Hirabayashi T; Yuguchi Y; Maeda M; Soeda Y; Hattori R; Gotoh M
Int J Urol; 2020 Dec; 27(12):1116-1123. PubMed ID: 32924152
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
